

# COMBACTE EPI-Net

## Development of Capabilities in Epidemiology

E. Tacconelli<sup>1</sup>, P. Gkolia<sup>1</sup>, N. Babu Rajendran<sup>1</sup>, A. Voss<sup>2</sup>, R. Schrijver<sup>2</sup>, M. Nunez<sup>3</sup>, J. Rodríguez-Baño<sup>3</sup>, F. Sifakis<sup>4</sup> and the EPI-Net Group



**Protocol finalised**  
**Inclusion of data started**  
**Lead: Jesús Rodríguez Baño**

### SUSPIRE

Systematic review of **SUR**veillance **S**ystems from **P**ublic health Institutions and scientific societies for antimicrobial **RE**sistance and HAls in humans

### AIM

To systematically assess all the organisations and scientific societies, providing regular data on frequency and/or distribution and/or determinants (contextual, patient, molecular/pathogen) of AMR **outside the ND4BB** programme in order to :

- Identify, catalogue and describe methodology used
- Analyse data for quality evaluation of representativeness, microbiological aspects, appropriateness of definitions, scopes, objectives and indicators, reporting and interpretation of data to assess their **strengths, gaps, limitations, mitigation actions and areas for improvement**



**Protocol finalised**  
**Lead: Andreas Voss**

**SURVAIL**  
**SUR**veillance of Antimicrobial resistance In **L**ivestock and **F**ood

### AIM

- Review of surveillance networks
- Review of network forming options
- Review of data sharing options
- Organise workshops with selected representatives of the surveillance systems to discuss face to face the advantages and possibility of combining them.
- **The ultimate aim is to reach an EU-wide real-time sentinel data network on antimicrobial resistance in livestock.**



**Protocol finalised**  
**Inclusion of data completed**  
**Analysis ongoing**  
**Lead: Evelina Tacconelli**

### EMBARGO

Systematic review of **EM**ergence and outbreaks of **Antibiotic-Resistant orG**anisms in **EurOpe**

### AIM


To examine **outbreaks of ARB**, and **define epidemiological variables associated with spreading and gaps and limitations of data reporting and areas for improvement.**

In collaboration with WP2 in DRIVE-AB (LEAD: Stephan Harbarth)



### Design EPI-Net Central Data Repository (CDR)

The operational model for the creation of the **EPI-Net Central Data Repository (CDR)** was discussed in details at the first EPI-Net annual meeting involving internal and external EPI networks



**2015 UPDATE**

### Development of a new Epidemiological Network

#### External EPI-Network

First engagement of expert's network from academia, public health experts, and health research foundations completed

#### ND4BB EPI-Network

- Contacts were established between ND4BB WP leads and EPI-Net
- Data sharing and patient's privacy issues were discussed and proposals for agreement developed

### Combacte-Magnet EPI-Net Newsletter

Sharing exciting project news and updates!

- Published bi-monthly
- For subscription, please contact with your name and e-mail address : Nithya.Babu-Rajendran @med.uni-tuebingen.de

### 2016 OBJECTIVES

- Completion of Systematic Reviews and Meta- Analyses
  - Definition of EPI-NET CDR operational model
  - Selection of collaborative projects

### CONTACT INFORMATION:

#### EPI-Net program management office:

Medizinische Klinik, Universitätsklinikum Tübingen, Otfried-Müller-Str. 10, 72076 Tübingen, Germany

Academic lead: **Evelina Tacconelli**, [evelina.tacconelli@med.uni-tuebingen.de](mailto:evelina.tacconelli@med.uni-tuebingen.de)

EFPIA lead: **Franciscos Sifakis**

[Franciscos.Sifakis@astrazeneca.com](mailto:Franciscos.Sifakis@astrazeneca.com)

Unique in its scale, ambition, and its potential benefits for patients, public health and pharmaceutical research in Europe, COMBACTE has the potential to become the powerhouse of anti microbial drug development in Europe that could serve as a standard for other groups. [Join us!](#)

Visit us at booth 37A in the exhibition hall.

[www.combacte.com](http://www.combacte.com) | [info@combacte.com](mailto:info@combacte.com)

### Authors Affiliation:

1. University Hospital (UKT)
2. Radboud University Nijmegen
3. University Hospitals Virgen Macarena and Virgen del Rocío in Seville, Spain (SAS)
4. AstraZeneca/Medimmune

